Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.

about

Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.

Item

http://www.wikidata.org/entity/Q47236288

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparative effectiveness and ...... n adults with type 2 diabetes.

@en

Comparative effectiveness and ...... n adults with type 2 diabetes.

@nl

type

Item

label

Comparative effectiveness and ...... n adults with type 2 diabetes.

@en

Comparative effectiveness and ...... n adults with type 2 diabetes.

@nl

prefLabel

Comparative effectiveness and ...... n adults with type 2 diabetes.

@en

Comparative effectiveness and ...... n adults with type 2 diabetes.

@nl

P1476

Comparative effectiveness and ...... in adults with type 2 diabetes

@en

P2093

Wilbert S Aronow

http://www.w3.org/2001/XMLSchema#string

P2860

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis

Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.

Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus.

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

P304

455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2017.08.43

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tatyana A. Shamliyan

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29285488

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5733315

http://www.w3.org/2001/XMLSchema#string